SLC5A2 and type 2 diabetes mellitus: Among these, the recent star of T2DM control and cardiovascular diseases, the SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibits reabsorption of glucose via the SGLT2 in the kidney and therefore lower blood sugar.